Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
Authors' conclusion
This real-world analysis of a large US claims database shows semaglutide was associated with early and significantly greater reductions in the risk of rMACE-3 and rMACE-5 versus tirzepatide among patients with overweight or obesity and ASCVD but without diabetes.
Study context
- Population
- Patients ≥45 years with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) (≥1 claim for myocardial infarction (MI), ischemic stroke or peripheral artery disease) without diabetes, insured US population (Komodo Research Data), first treated 13/5/2022–31/1/2025matched cohorts
- Participants
- 10,625 vs 10,625
- Exposure
- Semaglutide vs tirzepatide
- Semaglutiden = 10,625
- Tirzepatiden = 10,625reference
- Outcome
- rMACE-3 (MI, stroke, all-cause mortality) and rMACE-5 (rMACE-3, coronary revascularization, hospitalisation for HF); time to first event
Methodological detailsobservational, propensity score matched
- Observational
- Propensity score matched
Main finding
As reported in the abstract
Hazard ratio (rMACE-3)
0.71
P = 0.046
29% risk reduction
Hazard ratio (rMACE-5)
0.78
P = 0.040
22% risk reduction
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| rMACE-3 and rMACE-5, per-protocol analysis (censored at discontinuation, gap >30 days)Semaglutide vs Tirzepatide · per-protocol analysis | HR (rMACE-3) 0.43 | P = 0.005 |
| rMACE-3 and rMACE-5, per-protocol analysis (censored at discontinuation, gap >30 days)Semaglutide vs Tirzepatide · per-protocol analysis | HR (rMACE-5) 0.57 | P = 0.003 |
Original publication
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER ). Diabetes Obes Metab. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →